High Prevalence of Preexisting HBV Polymerase Mutations in Pregnant Women Does Not Limit the Antiviral Therapy Efficacy
Table 2
Potential NAs mutation at 29 positions of HBV reverse transcriptase analyzed in the 73 pregnant women.
Mutations type
Relationship with therapy
The proportion of the patients with mutations, n (%) (n = 73)
The frequency of the (%)
Patients with mutations frequency>20%, n (%)
Primary resistance mutations
rtI169T
ETV
0
0
0
rtA181T/V
LAM, TBV, ADV, TDF
4 (5.5)
0.023 ± 0.020
0
rtT184A/C/F/G/I/L/M/S
ETV
52 (71.2)
0.13 ± 0.14
14 (19.2%)
rtA194T
ADV, TDF
0
0
0
rtS202C/G/I
ETV
1 (1.4)
0.01
0
rtM204I/V
LAM, ETV, TBV
30 (41.1)
0.13 ± 0.11
7 (9.6%)
rtN236T/A
ADV, TDF
39 (53.4)
0.10 ± 0.13
4 (5.5%)
rtM250I/L/V
—
41 (56.2)
0.11 ± 0.08
5 (6.8%)
Compensatory mutations
rtL80I/V
LAM
11 (15.1)
0.02 ± 0.01
—
rtV173L
LAM
0
0
0
rtL180M
LAM, ETV, TBV
0
0
0
Putative NAs mutations
rtL82M
LAM
0
0
0
rtV84M
ADV
2 (2.7)
0.01 ± 0.001
0
rtS85A
ADV
0
0
0
rtI91L
LAM
40 (54.8)
0.82 ± 0.30
36 (49.3%)
rtA200V
LAM
1 (1.4)
0.02
0
rtV207I
LAM
0
0
0
rtS213T
ADV
3 (4.1)
0.11 ± 0.16
1 (1.4%)
rtV214A
ADV
3 (4.1)
0.01 ± 0.004
0
rtQ215P/S
LAM, ADV
12 (16.4)
0.07 ± 0.08
2 (2.7)
rtL217R
ADV
0
0
0
rtE218D
ADV
1 (1.4)
0.52
1 (1.4)
rtF221Y
ADV
30 (41.1)
0.29 ± 0.25
16 (21.9)
rtL229G/V/W
LAM
24 (32.9)
0.05 ± 0.06
1 (1.4)
rtI233V
ADV
30 (41.1)
0.12 ± 0.11
7 (9.6)
rtP237H
ADV
22 (30.1)
0.02 ± 0.02
0
rtN/H238D/S/T/A
ADV
46 (63.0)
0.15 ± 0.12
7 (9.6)
rtY245H
ADV
1 (1.4)
0.13
0
rtS/C256G
LAM, ETV
0
0
0
The prevalence of mutations were expressed as number of patients (percentages) and the mutation frequencies were expressed as mean ± standard deviation. Abbreviations: ADV, adefovir dipivoxil; ETV, entecavir; HBV, hepatitis B virus; LAM, lamivudine; n, number; NA, nucleoside/nucleotide analogues; TBV, telbivudine; TDF, tenofovir disoproxil fumarate.
